Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Multicenter Observational Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice

NCT06907082 is registered in ClinicalTrials.gov with Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia as lead sponsor.

NCT NCT06907082
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06907082 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Multicenter Observational Study to Evaluate the Efficacy and Safety of Neoadjuvant Treatment Based on Dual Blockade With Pertuzumab and the Trastuzumab Biosimilar CT-P6 (Herzuma®) in Early HER2-positive Breast Cancer in Routine Clinical Practice
Lead sponsor
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Phase
Not applicable
Overall status
Completed
Start date
December 28, 2020
Completion date
March 14, 2024
Enrollment
106 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer